Scoring criteria for determining the safety of liver resection for malignant liver tumors

Table 1 Clinical demographics of the patients who underwent liver resection for malignant tumors in the no liver dysfunction group (n = 78) and liver dysfunction group (n = 8)

Clinical variables / characteristics	Total values (n = 86)	No liver dysfunction (n = 78)	Liver dysfunction (n = 8)	P-values
Age (yr)	67.0 ± 10.3	66.8 ± 10.5	68.7 ± 9.3	NS
BSA (cm2)	1.61 ± 0.18	1.60 ± 0.18	1.65 ± 0.18	NS
Albumin (g/dL)	4.0 ± 0.4	4.0 ± 0.4	3.8 ± 0.4	NS
Bilirubin (mg/dL)	0.7 ± 0.3	0.6 ± 0.3	0.8 ± 0.4	NS
PT (%)	93.4 ± 11.9	93.9 ± 12.1	88.4 ± 9.7	NS
ICGR15 (%)	9.0 ± 4.6	8.4 ± 4.3	14.9 ± 2.5	< 0.001
HH15	0.578 ± 0.079	0.575 ± 0.078	0.617 ± 0.010	NS
LHL15	0.940 ± 0.027	0.940 ± 0.028	0.935 ± 0.024	NS
ATIII (%)	94.9 ± 17.2	96.0 ± 17.3	83.9 ± 13.4	0.036
Intraoperative bleeding (mL)	481.2 ± 468.5	455.8 ± 472.4	675.0 ± 430.0	NS
Operative time (min)	404.5 ± 135.2	390.8 ± 129.3	525.9 ± 140.9	0.014
Sex (male:female)	49:37	44:34	5:3	NS
Background (HCC: meta or CCC)	57:29	49:29	8:0	0.047
Hr (0/S:1:2/3)	53:17:16	49:16:13	4:1:3	NS
Sapporo score	13.2 ± 2.4	13.4 ± 2.5	11.0 ± 3.2	0.037
MELD score	7.6 ± 1.6	7.6 ± 1.7	7.8 ± 0.7	0.103
Child-Pugh score	3.2 ± 0.4	3.2 ± 0.4	3.4 ± 0.5	0.119
Total liver volume (cc)	1137.8 ± 222.9	1136.2 ± 228.5	1153.5 ± 221.4	NS
Reduction in liver volume (%)	19.0 ± 13.0	17.6 ± 12.1	32.8 ± 15.0	0.006
Residual liver volume (%)	85.1 ± 14.4	86.0 ± 13.7	75.4 ± 17.9	0.039

Continuous variables are expressed as the mean and standard deviation. BSA: Body surface area; PT-INR: Prothrombin time-international normalized ratio; ICG15: Indocyanine green retention rate at 15 min; ATIII: Serum anti-thrombin III level; HCC: Hepatocellular carcinoma; meta: Metastatic tumor; CCC: Cholangiocellular carcinoma; Hr: Hepatic resection; HH15: Uptake ratio of the heart at 15 min to that seen at 3 min on 99m Tc-galactosyl human serum albumin scintigraphy (GSA); LHL15: The uptake ratio of the liver to the liver plus heart at 15 min on GSA; MELD: Model For End-Stage Liver Disease; NS: Not significant.